Sienna Biopharmaceuticals, Inc. Accumulated Other Comprehensive Income
Sienna Biopharmaceuticals, Inc. had Accumulated Other Comprehensive Income of $1.30 million as of 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2019-11-12
- 2019-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $1.30M.
- 2019-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $2.77M.
- 2019-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $2.19M.
- 2018-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $3.20M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2019-09-30 | $1.30M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $2.77M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $2.19M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $3.20M 10-Q · filed 2019-11-12 |
| 2018-09-30 | $3.85M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $4.25M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $6.74M 10-Q · filed 2018-05-14 |
| 2017-12-31 | $5.37M 10-K · filed 2019-03-14 |
| 2017-09-30 | $4.70M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $3.11M 10-Q · filed 2017-09-07 |
| 2016-12-31 | -$366.00K 10-K · filed 2018-03-15 |